Unlike large pharma where novel projects compete with established, safer alternatives, biotech startups derive immense power from their singular focus. The "live or die" mentality on a single hard problem forces teams to innovate and persevere through setbacks, which is essential for pushing true scientific boundaries.

Ipsen's drug Icorvo, which failed in the large NASH market, found unexpected success in the rare liver disease PBC. The smaller market is growing faster than anticipated due to physicians treating patients earlier and a key competitor being withdrawn. This demonstrates how a failed asset can be repurposed for a highly successful niche application.

K-36's lead drug was acquired from Novartis not because it was a failed asset, but because it became available during a strategic reorganization. This illustrates a key opportunity for biotech startups: licensing promising preclinical assets that no longer fit a large pharmaceutical company's immediate development focus.

Roivant's early success came from identifying and building companies around promising drug assets that were deemed non-strategic by large pharmaceutical firms. This approach capitalized on undervalued IP and focused execution, pre-dating the now-common trend of pharma spin-outs.

To survive, Exelixis made the difficult decision to shut down its entire drug discovery operation, the company's historical foundation. This strategic move conserved cash and focused all resources on two late-stage clinical trials, betting the company's future on their success.

In the rare disease space, success hinges on deep patient community engagement. Smaller, nimbler biotechs often excel at creating these essential personal ties, giving them a significant advantage over larger pharmaceutical companies.

Contrary to most industries, scale is not a decisive advantage in drug discovery. Wellington's Jean Hynes notes that small, nimble biotech companies discover roughly half of all new drugs. This creates a perpetual opportunity for investors to back small firms that can generate massive value.

As large pharmaceutical companies shift focus to acquiring clinically validated assets, a gap has emerged in early-stage development. Smaller and mid-sized pharmas, unable to compete on price for late-stage assets, are now incentivized to take on more risk and partner earlier, driving innovation.

While large pharma companies invested heavily in RNAi and failed to produce candidates, Alnylam maintained a singular focus. They pushed their technology into human trials to learn and validate it, ultimately succeeding where better-funded competitors with a less focused, product-driven approach failed.